Technology | March 15, 2010

Can PEM Reduce unnecessary Breast Biopsies?

March 15, 2010 - Researchers released new data from an National Institute of Health (NIH) sponsored, multi-site study of hundreds of women with newly diagnosed breast cancer shows that positron emission mammography (PEM) may reduce unnecessary breast biopsies.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase. PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. and have been commercially available since 2007.

The NIH-sponsored multi-site study (NIH Grant 5R44CA103102) examined women with newly-diagnosed breast cancer. Patients were accrued from six leading clinical centers across the country: ARS Johns Hopkins Green Spring, Boca Raton Community Hospital, Scripps Clinic-Scripps Green Hospital, University of North Carolina, University of Southern California Norris Cancer Center, and Anne Arundel Medical Center.

The study found that PEM was significantly more precise at identifying benign and cancerous lesions, a positive predictive value (PPV), therefore reducing the number of unnecessary biopsies. A common physician complaint regarding the use of Breast MRI is its tendency to identify suspicious lesions, requiring biopsies on lesions that ultimately are found to be benign.

This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma associated with biopsies and for payors looking to reduce the costs associated with unnecessary procedures. The 388 woman study showed that PEM not only demonstrated a six percent improvement in specificity at comparably high sensitivity, but that PEM also had 31 fewer unnecessary biopsies and 26 percent higher PPV than Breast MR. These results are also particularly significant for those women who cannot tolerate an MR exam and require an alternate imaging tool.

"The results of this study mean that not only do physicians have an additional, powerful tool to help treat breast cancer but that PEM is a legitimate and better alternative for the 16 percent of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus, or gadolinium reaction," said Wendie Berg, M.D., Ph.D. and Principal Investigator for the trial. Berg recently published an article in the January 2010 issue in the journal Radiology examining the reasons why high-risk women who were recommended for a MR breast screening test refused to take the exam.

Related Content

Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...
Women Prefer Getting Mammograms Every Year
News | Mammography | January 09, 2018
Women prefer to get their mammograms every year, instead of every two years, according to a new study presented at the...
Planmed Clarity 2-D Digital Mammography System Receives FDA Approval
Technology | Mammography | January 08, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the Planmed Clarity 2-D full-field digital...
Overweight Women May Need More Frequent Mammograms
News | Mammography | January 04, 2018
Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become...
About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

About 25 percent of screening patients and 60 percent of diagnostic patients do not have prior mammograms available for comparison at the time of their examinations due to the lack of interoperability or other restrictions preventing clinicians from accessing prior exams.

Feature | Breast Imaging | January 02, 2018 | Kathryn Pearson Peyton, M.D.
Sixty million women undergo regular screening mammography in the United States, but even in the digital age, it is di
Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes
News | Oncology Diagnostics | January 02, 2018
Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
Double Black Announces Gemini Series Monitors for Multimodality and Digital Breast Imaging
Technology | Flat Panel Displays | December 28, 2017
December 28, 2017 — Double Black Imaging and their Image Systems Division are releasing their Gemini Series 6MP and 8
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
The Philips IQon Elite debuted at RSNA 2017 with features designed for emergency and trauma imaging. #RSNA2017, #RSNA17

The Philips IQon Elite debuted at RSNA 2017 with features designed for emergency and trauma care, as well as oncology. Image courtesy of Philips Healthcare

 

Feature | RSNA 2017 | December 21, 2017 | Greg Freiherr
The tenets of value-based medicine rippled across the exhibit floor like waves from a stone tossed in a pond.
Overlay Init